Ligand Pharmaceuticals CEO John Higgins retires; Todd Davis appointed CEO effective Dec 5, 2022

LIGAND PHARMACEUTICALS INC

John L. Higgins retired as CEO effective Dec 5, 2022; will resign from board Dec 31; receives 18 months salary, full equity vesting at target, and 2-year option extension.
Todd C. Davis, a board member, appointed CEO; base salary $650k, target bonus 60% of salary, and 132k stock options vesting over 4 years.
Davis severance: 18 months salary if terminated without cause pre-change-of-control; 2x salary + 2x max target bonus plus 24 months health if within 24 months post-change-of-control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John L. Higgins

Member of the Board

LGND · LIGAND PHARMACEUTICALS INC

Effective: 2022-12-31
Filed: December 5, 2022, 6:59 PM ET

Mr. Higgins also resigned as a member of the Board, effective December 31, 2022.

Departed

John L. Higgins

Chief Executive Officer

LGND · LIGAND PHARMACEUTICALS INC

Effective: 2022-12-05
Successor: Todd C. Davis
Filed: December 5, 2022, 6:59 PM ET

John L. Higgins has retired as Chief Executive Officer of the Company

Appointed

Todd C. Davis

Chief Executive Officer

LGND · LIGAND PHARMACEUTICALS INC

Effective: 2022-12-05
Filed: December 5, 2022, 6:59 PM ET

Todd C. Davis was appointed Chief Executive Officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John L. Higgins resigned as Member of the Board at LIGAND PHARMACEUTICALS INC.

Action: resigned
Role: Member of the Board

Exact text from the filing

Mr. Higgins also resigned as a member of the Board, effective December 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John L. Higgins retired as Chief Executive Officer at LIGAND PHARMACEUTICALS INC.

Action: retired
Role: Chief Executive Officer

Exact text from the filing

John L. Higgins has retired as Chief Executive Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Todd C. Davis was appointed as Chief Executive Officer at LIGAND PHARMACEUTICALS INC.

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Todd C. Davis was appointed Chief Executive Officer of the Company

View on SEC.gov

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000886163-22-000137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.